https://www.selleckchem.com/pr....oducts/sgc-cbp30.htm
04) different in the N-acetylcysteine group during the second post-operative week (0.14 . 0.15 mg/dL). There was no significant difference in the incidence of early allograft dysfunction (21% . 14%, p=0.327), and the survival rate (p=0.409). Peri-operative infusion of N-acetylcysteine in both donor and recipient would effectively prevent post-reperfusion syndrome and renal insufficiency. However, it might not affect the early allograft dysfunction, ICU stay, and mortality. NAC increases the chance of re-operation due to non-surgical b
Like
Comment
Share
